https://pharma.economictimes.indiatimes.com/news/drug-approvals-and-launches/us-fda-approves-amgens-uplizna-as-first-treatment-for-rare-immune-disorder/119961182
Amgen Uplizna: US FDA approves Amgen's Uplizna as first treatment for rare immune disorder, ETPharma
Amgen Uplizna: The drug, also known as inebilizumab, has now become the first FDA-approved treatment for Immunoglobulin G4-related disease (IgG4-RD), a rare...